Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (4.498.931 €): Patienten aktiv in Forschung und Dialogen für eine verbesserte Generation von Arzneimitteln: Förderung einer sinnvollen Patientenbindung im Lebenszyklus von Arzneimitteln … Hor 01.03.2018 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Patienten aktiv in Forschung und Dialogen für eine verbesserte Generation von Arzneimitteln: Förderung einer sinnvollen Patientenbindung im Lebenszyklus von Arzneimitteln für bessere gesundheitspolitische Ergebnisse.
PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE. PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures. PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come. PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.
Geförderte Unternehmen:
Quelle: https://cordis.europa.eu/project/id/777450
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.